Tempus AI stock surged 40% YTD, driven by acquisitions and investor confidence in healthcare AI. Can its momentum spark ...

Tempus AI leverages AI for treatment decisions and diagnostics, thriving in the booming healthcare AI market with strong ...

Myriad and its partners in the suit says that even though the patents on the natural genes are invalidated, Gene by Gene and Ambry Genetics are still in violation of 10 patents on the BRCA gene ...

Ambry Genetics drives innovation in diagnostics by launching cutting-edge genetic tests and technologies. Its broad collaborations, novel research projects, and networks for data sharing ...

Marcy Richardson from Ambry Genetics discusses the importance of a new study that assessed the functional impact of thousands of BRCA2 variants, identifying those that may increase cancer risk. What ...

For the full year, the Data and Services division was a key contributor. The acquisition of Ambry Genetics, finalized in February 2025, further strengthens Tempus’ genomics capabilities by ...

Tempus AI's acquisition of Ambry Genetics, finalized on February 3, 2025, for $375 million in cash and $225 million in stock, has significantly boosted investor confidence. This strategic move ...

Management guides for $1.24 billion in 2025 revenues, a 79% YoY growth, bolstered by the Ambry Genetics acquisition and a rapidly growing TAM. Despite the deep selloff recently, I rank TEM a ...

Linh H. Le is an accomplished finance and accounting executive with extensive knowledge and expertise that he has implemented at such companies as Ambry Genetics, Medtronic, Disney, Fox ...

The United States genetic testing market is poised for substantial growth, projected to expand from USD 4.71 billion in 2021 to approximately USD 12.08 billion by 2028, with a robust CAGR of 14.50%.